Shield Therapeutics doubles Q2 revenue and sets sights on 2025 profitability with ACCRUFeR momentum Podcast Por arte de portada

Shield Therapeutics doubles Q2 revenue and sets sights on 2025 profitability with ACCRUFeR momentum

Shield Therapeutics doubles Q2 revenue and sets sights on 2025 profitability with ACCRUFeR momentum

Escúchala gratis

Ver detalles del espectáculo
Shield Therapeutics is riding a wave of commercial momentum, reporting strong second-quarter financial results and outlining an ambitious path to profitability in 2025. CEO Anders Lundstrom and CFO Santosh Shanbhag joined Steve Darling from Proactive to break down the company’s performance and growth strategy. Shanbhag revealed that Q2 net revenue from ACCRUFeR surged to $12.8 million, nearly doubling the first quarter’s numbers. The company also saw a record 47,000 prescriptions for ACCRUFeR, marking its highest-ever quarterly performance since launch. With $10.8 million in cash on hand at the quarter’s end, Shield remains on track to achieve cash flow positivity by late 2025. Lundstrom credited ACCRUFeR’s unique oral iron formulation—which delivers improved tolerability over traditional iron supplements—as a key differentiator in the iron deficiency market. He also pointed to Shield’s U.S.-focused commercialization strategy, including a collaboration with Viatris, as central to the company’s accelerating prescription growth. Shield is also pursuing regulatory label expansion into pediatric populations, with filings submitted in the U.S., UK, and EU. Additional commercial agreements in Japan and milestone payments from partners are helping to further build the company’s international revenue base. Lundstrom attributed the successful Q2 performance to strategic digital marketing investments and a realignment of Shield’s U.S. sales force, which he said is now “working really, really nicely together.” With momentum building across multiple fronts, Shield Therapeutics appears well-positioned to transform its lead product, ACCRUFeR, into a market leader—while transitioning the company into a cash-flow-positive business within the next 18 months. #proactiveinvestors #shieldtherapeutics #aim #ftse #stx #otcqb #shief #ACCRUFeR #IronDeficiency #BiotechNews #HealthcareStocks #Q2Results #SantoshShanbhag #AndersLundstrom #CashFlowPositive #PediatricIronTherapy #InvestorUpdate #FDAFiling #PharmaGrowth
Todavía no hay opiniones